KD025 (Belumosudil) is a potent, selective ATP-competitive ROCK2 inhibitor. It affects TGF-β/SMAD and IL-17/STAT3 signaling by competitively binding to the kinase active site, effectively inhibiting fibrosis, epithelial-mesenchymal transition, and pro-inflammatory cytokine production.
KD025 (Belumosudil) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for KD025 (Belumosudil) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.